Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2029-11-30
Target enrollment:
Participant gender:
Summary
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain
due to prostate cancer will be treated on an open label study to evaluate effectiveness of
sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose
testosterone in sequence with enzalutamide to improve primary and secondary outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Panbela Therapeutics Prostate Cancer Foundation United States Department of Defense